Diversification via an ETF can help biotech investors avoid boom-or-bust volatility while still capitalizing on long-term growth trends.

T. Rowe Price recently expanded its exchange traded lineup by launching three fully transparent, actively managed equity ETFs on NASDAQ: a biotech ETF (TDNA, expense ratio 0.55%), a small-cap ETF ...

The iShares Biotechnology ETF offers diversified exposure to the biotech sector, focusing on large-cap leaders while maintaining positions in smaller innovators. IBB is cap-weighted and top-heavy, ...

Biotech firms have been increasingly directing capital toward oncology therapeutics in recent years, reflecting a structural shift as companies recognize the significant commercial potential of ...

The total cost of owning an exchange-traded fund can be roughly split into two parts: holding costs and transaction costs. Holding costs come with owning an ETF. Trading costs are paid as investors ...

Investors continue to pour money into defined outcome, or “buffer” exchange-traded funds. For their providers, however, success is not guaranteed nor equally distributed. Across $78 billion invested ...